药物毒性警示结构综述

综述：药物毒性警示结构

摘要：

药物毒性是指在治疗疾病过程中，药物对机体产生的不良反应。药物毒性的发生可能导致轻微的不适或严重的生命威胁。因此，药物毒性警示结构的设计和应用对于保证药物的安全性和有效性具有重要意义。本综述旨在探讨不同类型的药物毒性警示结构，包括药物毒性测试方法、药物毒理学数据库以及机器学习在药物毒性预测中的应用。通过对药物毒性警示结构的研究和应用，可以提高药物研发的效率和成功率，同时降低不良反应的风险。

1. 引言

药物毒性是药物研发和临床使用中的一大挑战。药物毒性不仅可能导致药物的失败，还可能对患者的健康带来严重的危害。因此，药物毒性警示结构的设计和应用具有重要的临床和经济意义。

2. 药物毒性测试方法

药物毒性测试方法是评估药物安全性和毒性的关键步骤。常用的药物毒性测试方法包括体外试验和体内试验。体外试验主要包括细胞毒性测试、酶抑制测试和细胞通透性测试等；体内试验则包括小鼠模型、大鼠模型和非人灵长类动物模型等。

3. 药物毒理学数据库

药物毒理学数据库是存储和管理药物毒性数据的重要资源。药物毒理学数据库可以为药物研发人员提供毒性数据和结构活性相关信息，帮助评估和预测药物的毒性。常用的药物毒理学数据库包括Toxicity Estimation Software Tool (TEST)、Chemical Safety Information from Intergovernmental Organizations (INCHEM)和Toxicology Data Network (TOXNET)等。

4. 机器学习在药物毒性预测中的应用

机器学习是一种能够从大量数据中学习和识别模式的计算方法。在药物毒性预测中，机器学习可以用于构建预测模型，通过分析药物结构和毒性数据，预测药物的毒性。常用的机器学习方法包括支持向量机、随机森林和深度学习等。

5. 药物毒性警示结构的应用

药物毒性警示结构的应用可以帮助药物研发人员评估和预测药物的毒性风险。通过结合药物毒性测试方法、药物毒理学数据库和机器学习等技术，可以提高药物研发的效率和成功率。同时，药物毒性警示结构的应用还可以帮助医生和患者更好地了解和管理药物的毒性风险。

6. 结论

药物毒性警示结构是保证药物的安全性和有效性的重要手段。通过不断的研究和应用，可以提高药物研发的效率和成功率，同时降低不良反应的风险。然而，药物毒性警示结构的设计和应用仍然需要进一步的研究和改进，以满足不断发展的药物研发和临床需求。

参考文献：

1. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-683.
2. Sipes NS, Martin MT, Kothiya P, et al. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013;26(6):878-895.
3. Tice RR, Austin CP, Kavlock RJ, et al. Improving the human hazard characterization of chemicals: a Tox21 update. Environ Health Perspect. 2013;121(7):756-765.
4. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31.
5. Huang R, Xia M, Nguyen D-T, et al. Tox21Challenge to Build Predictive Models of Nuclear Receptor and Stress Response Pathways as Mediated by Exposure to Environmental Chemicals and Drugs. Front Environ Sci. 2016;3:85.
6. Luechtefeld T, Marsh D, Rowlands C, Hartung T. Machine learning of toxicological big data enables read-across structure activity relationships (RASAR) outperforming animal test reproducibility. Toxicol Sci. 2018;165(1):198-212.
7. Wang Y, Xiao J, Suzek TO, et al. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 2009;37(Database issue):D623-623D633.
8. Wang Y, Suzek T, Zhang J, et al. PubChem BioAssay: 2014 update. Nucleic Acids Res. 2013;42(D1):D1075-1075D1082.
9. Kavlock R, Chandler K, Houck K, et al. Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem Res Toxicol. 2012;25(7):1287-1302.
10. Sauer JM, Chappell VA. Use of high-throughput in vitro toxicity screening data in cancer hazard evaluations by IARC Monograph Working Groups. ALTEX. 2016;33(3):261-273.
11. Druzhilovsky DS, Onopchenko OV, Varlamova EV, et al. Comparative analysis of toxic and non-toxic compounds using the random forest algorithm. J Cheminform. 2019;11(1):55.
12. Gao J, Ouyang W, Kang S, et al. Chemical space expansion of small molecules for drug discovery. Mol Inform. 2018;37(5-6):1700123.
13. Hoja H, Yli-Harja O, Idänpään-Heikkilä J, et al. A novel method for drug toxicity prediction using drug-drug interactions. BMC Med Inform Decis Mak. 2015;15(1):1-10.
14. Zhu F, Han B, Kumar P, et al. Update of TTD: therapeutic target database. Nucleic Acids Res. 2010;38(Database issue):D787-787D791.
15. Zhang L, Tan J, Han D, Zhu H, Fromm M, König J. Quinidine Is a Highly Specific Inhibitor of the Organic Cation Transporter 1 (OCT1) in Comparison to MATE1 and MATE2-K. Mol Pharm. 2016;13(6):1947-1954.
16. Zhu F, Han B, Kumar P, et al. Update of TTD: therapeutic target database. Nucleic Acids Res. 2010;38(Database issue):D787-787D791.
17. Rostkowski M, Ekins S, Drwal M, et al. Mining chemical toxicity using structural alerts and Pass/Pamm models. Chem Res Toxicol. 2008;21(7):1400-1409.
18. Kinsella N, Haynesworth A, Everett L, et al. A unit operation approach to modeling drug toxicity. Chem Res Toxicol. 2011;24(7):1147-1155.
19. Sridhar J, Shankar B. A review on the association between cancer and drug-induced liver injury. Hepatol Res. 2016;46(10):936-950.
20. Zhao YH, Abraham MH, Le J, et al. Rate-limited Steps of Human Oral Absorption and QSAR Studies. Pharm Res. 2002;19(9):1446-1457.
21. Klopman G, Rosenkranz HS. MobyDigs: A Novel Molecular Electron Density Shape Algorithm for Quantitating the Potential Chemical Toxicity of Organic Chemicals in Biological Systems. J Chem Inf Model. 1999;39(6):1162-1174.
22. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol. 2007;152(1):21-37.
23. Liu R, Yu X, Wallqvist A. Data-Driven Prediction of Drug Effects and Interactions. Science. 2009;323(5918):261-264.
24. Ekins S, Williams AJ, Xu JJ. Advancing Drug Discovery with Computational Biology and Chemistry; Springer: 2014.
25. Hanser T, Barber C, Rappaport SM, et al. Cheminformatics Analysis of Assertions Mined from Literature That Describe Drug-Induced Liver Injury in Different Species. Chem Res Toxicol. 2011;24(8):1251-1262.
26. Zhu F, Shi Z, Qin C, et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012;40(D1):D1128-1128D1136.
27. Huang R, Southall N, Wang Y, et al. The NCGC Pharmaceutical Collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Science Translational Medicine. 2011;3(80):80ps16-80ps16.
28. Chen X, Wu Q-F, Yan G-Y. RKNN-MKL: A Novel Multi-label Learning Method for the Classification of Multi-drug Combinations. Mol Ther Nucleic Acids. 2018;10:270-279.
29. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31.
30. Wang Y, Xiao J, Suzek TO, et al. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 2009;37(Database issue):D623-623D633.